Andrew Schiff - Managing Partner @ Aisling Capital

Start Free Trial

Pricing

Overview

Number of Portfolio Companies

Number of Current Board & Advisor Roles

Primary Job Title Managing Partner
Primary Organization
Aisling Capital

Location New York, New York, United States
Regions Greater New York Area, East Coast, Northeastern US
Gender Male

Investor Type
obfuscated
obfuscation

LinkedIn View on LinkedIn

Andrew N. Schiff is based out of Jupiter, Florida, and is the Managing Partner of Aisling Capital. Andrew previously worked at New York Presbyterian Hospital as a practiced internal medicine. Andrew N. Schiff attended the Cornell University.

Personal Investments

Number of Investments

Andrew Schiff

invested in

Plant Culture Systems

obfuscation

. This investment -

Pre Seed Round - Plant Culture Systems

- was valued at

obfuscation

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Plant Culture Systems	No	Pre Seed Round - Plant Culture Systems	obfuscated obfuscation

Partner Investments

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Forge Biologics	Aisling Capital	Yes	Series C - Forge Biologics	obfuscated obfuscation
obfuscated obfuscation	Dren Bio	Aisling Capital	Yes	Series B - Dren Bio	obfuscated obfuscation
obfuscated obfuscation	Monte Rosa Therapeutics	Aisling Capital	Yes	Series B - Monte Rosa Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Zavante Therapeutics	Aisling Capital	—	Series A - Zavante Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Agile Therapeutics	Aisling Capital	No	Post-IPO Equity - Agile Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Miramar Labs	Aisling Capital	No	Series D - Miramar Labs	obfuscated obfuscation
obfuscated obfuscation	Agile Therapeutics	Aisling Capital	Yes	Series C - Agile Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Zeltiq Aesthetics	Aisling Capital	Yes	Series D - Zeltiq Aesthetics	obfuscated obfuscation
obfuscated obfuscation	Asensus Surgical	Aisling Capital	Yes	Post-IPO Equity - Asensus Surgical	obfuscated obfuscation
obfuscated obfuscation	Sirion Therapeutics	Aisling Capital	Yes	Series B - Sirion Therapeutics	obfuscated obfuscation

Jobs

Number of Current Jobs

Andrew Schiff

is the

Managing Partner

Aisling Capital

Aisling Capital Managing PartnerSep 1999

Board and Advisor Roles

Number of Current Board & Advisor Roles

Andrew Schiff

holds

board and advisor roles including

Board Member

Dren Bio

Board Member

Monte Rosa Therapeutics

, and

Board of Directors

Zeltiq Aesthetics

Dren Bio Board MemberJun 2022
Monte Rosa Therapeutics Board MemberSep 24, 2020
Zeltiq Aesthetics Board of DirectorsJul 2010
SkinMedica Board of DirectorMar 5, 2004
ArgiNOx Phamaceuticals Board of Directors
Cardiokine Board of Directors
Asensus Surgical Board of Directors
Quintiles Board of Directors
Myogen Board of Directors
Barrier Therapeutics Board of Directors

Related Hubs

Hub Name	CB Rank (Hub)
Northeastern US Investors with Funds Raised in 2009	86,595
Investors with Funds Raised in 2009	27,860
City of New York Investors	4,109
Private Equity Firms with Investments in Greater New York Area	8,862
City of New York Early Stage Venture Investors	16,619
Late Stage Venture Investors with Investments in New York, New York	4,185
Greater New York Area Venture Stage Investors	33,027
Greater New York Area Post IPO Investors	54,615
New York Private Equity Firms	16,578
East Coast Private Equity Firms	8,019